Welcome to our dedicated page for Travere Therapeutics SEC filings (Ticker: TVTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Travere Therapeutics, Inc. (TVTX) provides access to the company’s official disclosures as a Nasdaq‑listed biopharmaceutical issuer focused on rare kidney, liver and metabolic diseases. Travere files periodic and current reports with the U.S. Securities and Exchange Commission under the Securities Exchange Act of 1934.
Recent Form 8‑K filings document press releases announcing quarterly and preliminary annual financial results, including net product sales and other financial metrics, as well as broader corporate updates. These reports specify when information is being furnished rather than filed for purposes of Section 18 of the Exchange Act and clarify that such information is not automatically incorporated by reference into registration statements unless expressly stated.
Travere also uses Form 8‑K to report material regulatory developments. For example, the company has filed 8‑Ks describing FDA communications on the supplemental New Drug Application (sNDA) for FILSPARI (sparsentan) in focal segmental glomerulosclerosis (FSGS), including the decision that an advisory committee meeting was no longer needed and confirmation of the Prescription Drug User Fee Act (PDUFA) target action date. Another 8‑K notes the FDA’s extension of the review timeline after the company submitted additional information characterized as a Major Amendment.
Through this page, users can review Travere’s financial reporting (10‑K and 10‑Q when available), current reports on significant events (8‑K), and other disclosures that describe the company’s clinical programs, commercial activities, risk factors and capital structure. Stock Titan enhances these filings with AI‑powered summaries that highlight key points in lengthy documents, helping readers quickly understand topics such as revenue drivers, R&D spending, regulatory interactions and forward‑looking statements. Real‑time updates from EDGAR and access to insider and executive transaction reports, when filed on forms such as Form 4, allow investors to monitor how management actions and regulatory events intersect with Travere’s strategy in rare diseases.
Perceptive Advisors LLC and affiliated entities report a significant minority stake in Travere Therapeutics, Inc. They beneficially own 4,278,180 shares of common stock, representing 4.8% of the company’s outstanding shares, based on 89,472,327 shares outstanding as of October 27, 2025.
The shares are directly held by Perceptive Life Sciences Master Fund, Ltd., with voting and investment power shared among the Master Fund, Perceptive Advisors, and Joseph Edelman. The group certifies the investment was not made to change or influence control of Travere Therapeutics.
Travere Therapeutics Inc. received an amended Schedule 13G/A from Macquarie entities indicating they no longer hold a reportable stake in the company’s common shares. Macquarie Group Limited, Macquarie Management Holdings Inc. and Macquarie Investment Management Business Trust each report beneficial ownership of 0 shares, or 0.00% of the class, as of 12/31/2025.
The filers state the securities referenced were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Travere Therapeutics.
Travere Therapeutics Inc received a major shareholder disclosure from State Street Corporation, which reported beneficial ownership of 4,756,666 Travere common shares, representing 5.3% of the class as of December 31, 2025.
State Street reports shared voting power over 4,485,757 shares and shared dispositive power over 4,756,666 shares, with no sole voting or dispositive authority. The position is certified as held in the ordinary course of business and not for changing or influencing control of Travere.
Travere Therapeutics, Inc. Chief Medical Officer Jula Inrig reported planned sales of company stock. On February 4, 2026, Inrig sold 1,547 Travere common shares at a weighted average price of $32.11 and an additional 232 shares at a weighted average price of $32.85.
These transactions were made under a written trading plan adopted on May 28, 2025 that meets Rule 10b5-1(c) requirements and include shares sold to cover tax obligations from vesting restricted stock units. Following these sales, Inrig directly held 105,706 Travere common shares.
Travere Therapeutics, Inc. chief financial officer Christopher R. Cline reported two open‑market sales of company common stock on February 4, 2026. He sold 1,635 shares at a weighted average price of $32.14 and 110 shares at $32.90, and continued to hold 111,226 shares directly afterward.
According to the filing, these transactions were executed under a pre‑established Rule 10b5‑1 trading plan adopted on May 28, 2025, and include sales to cover tax obligations arising from the vesting of restricted stock units.
Travere Therapeutics Chief Legal Officer Elizabeth E. Reed reported planned stock sales under a Rule 10b5-1 trading plan. On February 4, 2026, she sold 2,485 shares of common stock at a weighted average price of $32.07 and 509 shares at a weighted average price of $32.74.
The filing notes that the plan was adopted on June 16, 2025 and that the transactions include shares sold to cover tax obligations from vesting restricted stock units. After these sales, Reed directly owned 105,211 shares of Travere Therapeutics common stock.
Elizabeth Reed filed a Rule 144 notice to sell 2,994 shares of common stock through Morgan Stanley Smith Barney LLC on or about 02/04/2026 on NASDAQ, with an aggregate market value of 96,360.09.
The filing also lists prior sales during the past three months: 7,175 shares of common stock sold on 02/03/2026 for gross proceeds of 230,463.88, and 10,000 shares sold on 01/20/2026 for gross proceeds of 273,420.00.
TVTX shareholder Jula Inrig has filed a Form 144 to sell 1,779 shares of common stock through Morgan Stanley Smith Barney LLC, with an aggregate market value of 57299.10. The proposed sale is expected around 02/04/2026 on the NASDAQ, where 89,472,327 common shares are outstanding.
The shares to be sold were acquired as restricted stock from the issuer on 01/31/2026. In the past three months, Jula Inrig has already completed several sales of TVTX common stock, including 15,000 shares for gross proceeds of 630004.50 and other smaller transactions disclosed in the filing.
Christopher Cline filed a notice of proposed sale of Travere Therapeutics common stock under Rule 144. The filing covers 1,745 common shares with an aggregate market value of $56,165.62, to be sold through Morgan Stanley Smith Barney LLC on NASDAQ around 02/04/2026.
The shares were acquired as restricted stock from the issuer on 01/31/2026. In the past three months, Cline also sold 20,000 common shares for gross proceeds of $700,200.00 and 7,242 common shares for gross proceeds of $232,616.03.
A shareholder filed a Rule 144 notice to sell 7,310 shares of common stock, with an aggregate market value of 234,799.04, through Morgan Stanley Smith Barney on or about 02/03/2026 on the NASDAQ. These shares were acquired via restricted stock unit vesting on 01/31/2026 as compensation from the issuer. The filing also notes that the seller, Peter Heerma, sold 4,980 common shares for gross proceeds of 199,200 on 12/24/2025. Shares outstanding were 89,472,327 common shares at the time referenced, which is a baseline figure and not the amount being sold.